Biomarkers in Hip Dysplasia: a Scoping Review

Background

Hip dysplasia is a congenital condition affecting around 5% of the population and is a major risk factor for secondary osteoarthritis and hip arthroplasty. While biomarkers have been widely studied in primary osteoarthritis, their role in hip dysplasia remains unclear.

Understanding biomarker profiles in this patient population may aid in the development of preventive and non-surgical treatment strategies, as well as monitoring the effects of surgical interventions and physical activity.

Objective

To systematically map and summarize the current evidence on biomarkers in patients with hip dysplasia.

Methods

This scoping review will follow the PRISMA-ScR guideline. Eligible studies include interventional and observational studies published in peer-reviewed journals reporting biomarker data in patients with hip dysplasia. Animal studies, conference abstracts, and studies not reporting hip dysplasia data separately will be excluded. We will search MEDLINE, Embase, and CENTRAL without study design or date restrictions, but limited to English-language publications. Two reviewers will independently screen studies and extract data, which will be synthesized in tables and summarized narratively.

Dissemination

The findings will be published in an international peer-reviewed journal and may inform research on disease-modifying treatments and prevention of osteoarthritis in hip dysplasia.

Study registration

This protocol is uploaded to MedRxiv.org

Funding

The review is investigator-initiated. Any costs in connection with the study will relate to the salary of the investigators and are provided by the department.